Mounjaro vs Victoza

Mounjaro (tirzepatide) and Victoza (liraglutide) are both FDA-approved for type 2 diabetes, but they sit at very different points in the incretin therapy timeline. Victoza, approved in 2010, was the first daily GLP-1 receptor agonist to demonstrate cardiovascular benefit in patients with type 2 diabetes (LEADER trial). Mounjaro, approved in 2022, is a dual GIP and GLP-1 receptor agonist that produces substantially greater A1C reduction and weight loss than any single-receptor GLP-1 agent. The dosing rhythms also differ — Mounjaro is weekly, Victoza is daily — which affects adherence patterns. There is no head-to-head trial of the two; clinicians infer the gap from each drug's benchmark studies.

Same Indication, Different Generations

Both Mounjaro and Victoza are FDA-approved as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes. Victoza is also approved for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease (added in 2017 based on LEADER), and for type 2 diabetes in patients aged 10 and older (added in 2019 based on ELLIPSE). Mounjaro currently has only the type 2 diabetes adjunct indication; the SURPASS-CVOT cardiovascular outcomes trial is ongoing and has not yet produced a labeled CV indication. The drug labeled with tirzepatide for chronic weight management is Zepbound; the drug labeled with liraglutide for chronic weight management is Saxenda at the higher 3 mg daily dose.

Mechanism, Dose, and Administration

Mounjaro is a dual agonist that binds and activates both the GIP receptor and the GLP-1 receptor — a combined incretin signal that enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central mechanisms. The dose range is 2.5 mg starter through 5, 7.5, 10, 12.5, and 15 mg maintenance, injected once weekly. Victoza is a single GLP-1 receptor agonist with a roughly 13-hour half-life that requires daily injection, titrated from 0.6 mg through 1.2 mg to a maximum of 1.8 mg. The same liraglutide molecule appears in Saxenda at higher doses (up to 3.0 mg daily) for weight management.

Efficacy Data

In the SURPASS clinical program, Mounjaro 15 mg weekly produced average A1C reductions of approximately 2.4 percentage points and weight loss of 11 to 12 kg over 40 to 72 weeks. SURPASS-2 head-to-head against Ozempic 1 mg showed Mounjaro superior across both endpoints. Victoza 1.8 mg daily in LEADER produced average A1C reduction of about 1.1 percentage points and weight loss of 2.8 kg over a median 3.8 years, with a 13 percent reduction in major adverse cardiovascular events compared with placebo. Direct comparison is limited by the lack of a head-to-head trial, but indirect evidence consistently favors Mounjaro for both glycemic control and weight effect.

Coverage and Practical Considerations

Both Mounjaro and Victoza are typically covered by commercial plans and Medicare Part D for type 2 diabetes with prior authorization. Victoza has a longer formulary history and faces generic liraglutide competition that launched in 2024, often resulting in lower out-of-pocket costs. Mounjaro is generally on preferred tiers when covered but increasingly faces step-therapy requirements through metformin, generic liraglutide, or other agents. For patients with established cardiovascular disease and type 2 diabetes, Victoza's labeled CV indication can simplify prior authorization. For patients prioritizing maximum glycemic control or who would also benefit from substantial weight loss, Mounjaro's superior efficacy typically justifies the additional approval steps.